Réseau Alzheimer à transmission prédominante (DIAN) (DIAN)
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Description détaillée
Dominantly inherited Alzheimer's disease (AD) represents less than 1% of all cases of AD and is an important model for study because the responsible mutations have known biochemical consequences that are believed to underlie the pathological basis of the disorder. Three major hypotheses will be tested:
- First, that there is a period of preclinical (presymptomatic) AD in individuals who are destined to develop early-onset dementia (gene carriers) that can be detected by changes in biological fluids and in neuroimaging correlates in comparison with individuals who will not develop early-onset dementia (non-carriers).
- Second, because all identified causative mutations for AD affect the normal processing of amyloid precursor protein (APP) and increase brain levels of amyloid-beta 42 (Aβ42), the sequence of preclinical changes initially will involve Aβ42 (production and clearance; reduced levels in cerebrospinal fluid [CSF]), followed by evidence for cerebral deposition of Aβ42 (amyloid imaging), followed by cerebral metabolic activity (functional imaging), and finally by regional atrophy (structural imaging).
- Finally, that the phenotype of symptomatic early-onset familial AD, including its clinical course, is similar to that of late-onset "sporadic" AD.
The following specific aims will be used to test these hypotheses:
-
Maintain the established international DIAN registry of individuals (MCs and non-carriers (NC), symptomatic and asymptomatic) who are biological adult children of an affected parent with an APP, PSEN1, or PSEN2 mutation causing AD and assess participants every 2 years with the uniform DIAN protocol.
-
Recruit to the registry 50 new asymptomatic participants, both MCs and NCs, in Year 1 of the next budget period to maintain the total DIAN cohort at ~250 individuals. These new participants will include those who are more than 15 years younger than the estimated age of symptomatic onset (EAO) to explore the earliest observable biomarker changes of preclinical AD.
-
Maintain the integrated DIAN database and biospecimen repository to disseminate data and tissue to qualified investigators (within and outside of DIAN) in a user-friendly manner and to permit analyses within, between, and among the various data domains that will include:
- In asymptomatic MCs (using NCs as controls), determine the temporal ordering and rate of intraindividual change in clinical, cognitive, imaging, and fluid biomarkers of AD prior to EAO
- In symptomatic MCs, compare the clinical and neuropathological phenotypes of ADAD to those of LOAD, using datasets such as ADNI.
-
Utilize the DIAN cohort and its database and biospecimen repository to support new scientific studies, including use of exome chip technology to examine potential modifiers of age at symptomatic onset. Pursue other new scientific initiatives that are funded independently of the DIAN grant but are conducted within the DIAN infrastructure at no cost to DIAN including: Dermal fibroblasts and induced pluripotent stem cells (iPSCs), examine biomarker surrogates for neurogeneration in CSF including Visinin-like protein-1 (VILIP-1), Tau seeding assay, Stable Isotope Leucine Kinetics (SILK) in DIAN participants, determine the exact Abeta species that underlie AD pathology using Mass spectrometry, exome sequencing on all DIAN participants to search for both positive and negative modifiers of EYO, and amyloid imaging crossover to [18F]florbetapir.
-
Provide genetic counseling to any and all DIAN participants who wish to learn their mutation status and, for those who decide to learn their status after counseling, provide genetic testing by Clinical Laboratory Improvement Amendments (CLIA)-approved laboratories (i.e., outside of DIAN).
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Alisha Daniels, MD,MHA
- Numéro de téléphone: (314) 273-9057
Sauvegarde des contacts de l'étude
- Nom: DIAN Obs Admin Core
- E-mail: NEURO-DIANCoordinatingCenter@email.wustl.edu
Lieux d'étude
-
-
-
Munich, Allemagne, D-81377
- Recrutement
- German Center for Neurodegenerative Diseases (DZNE) Munich, and University Hospital Ludwig-Maximilians-Universitat (LMU) Munich
-
Chercheur principal:
- Johannes Levin, MD, PhD
-
Contact:
- Ilona Ruge
- E-mail: Ilona.Ruge@dzne.de
-
Tübingen, Allemagne, D-72076
- Recrutement
- German Center for Neurodegenerative Diseases (DZNE) Tübingen and Hertie-Institute for Clinical Brain Research, University of Tübingen
-
Chercheur principal:
- Mathias Jucker, PhD
-
Contact:
- Beatrice Spring
- E-mail: beatrice.spring@med.uni-tuebingen.de
-
-
-
-
-
Buenos Aires, Argentine
- Recrutement
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia" (FLENI) Instituto de Investigaciones Neurológicas Raúl Correa
-
Contact:
- Patricio Chrem, MD
- Numéro de téléphone: 20565342
- E-mail: pchremmendez@fleni.org.ar
-
Chercheur principal:
- Ricardo Allegri, MD, PhD
-
-
Salta Province
-
Salta, Salta Province, Argentine
- Recrutement
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI)
-
Chercheur principal:
- Ricardo Allegri, MD, PhD
-
Contact:
- Patricio Chrem
- E-mail: pchremmendez@fleni.org.ar
-
-
-
-
New South Wales
-
Sydney, New South Wales, Australie, 2031
- Recrutement
- Neuroscience Research Australia
-
Contact:
- Jacob Bechara
- E-mail: j.bechara@neura.edu.au
-
Contact:
- William Brooks, MBBS, MPH
- E-mail: w.brooks@NeuRA.edu.au
-
Chercheur principal:
- Emma Devenney, PhD, FRACP
-
-
Victoria
-
Melbourne, Victoria, Australie, 3130
- Suspendu
- Mental Health Research Institute, University of Melbourne
-
-
Western Australia
-
Perth, Western Australia, Australie, 6009
- Recrutement
- Sir James McCusker Alzheimer's Disease Research Unit, Edith Cowan University
-
Contact:
- Kevin Taddei
- Numéro de téléphone: +61-(0)8-6304-5107
- E-mail: k.taddei@ecu.edu.au
-
Chercheur principal:
- Ralph Martins, PhD
-
Contact:
- Samantha Gardener
- E-mail: s.gardener@ecu.edu.au
-
-
-
-
São Paulo
-
São Paulo, São Paulo, Brésil, 05403-900
- Recrutement
- Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo
-
Chercheur principal:
- Leonel Tadao Takada, MD, PHD
-
Contact:
- Aline Nishizawa
- E-mail: anishizawa1@gmail.com
-
Contact:
- Carreira Luzia Lima
- E-mail: luzia.carreira@hc.fm.usp.br
-
-
-
-
Quebec
-
Verdun, Quebec, Canada, H4H 1R3
- Pas encore de recrutement
- McGill University Research Centre for Studies in Aging
-
Contact:
- Tamar Tatigian
- E-mail: tamar.tatigian@mcgill.ca
-
Chercheur principal:
- Pedro Rosa-Neto, MD,PhD
-
-
-
-
Colombia
-
Medellín, Colombia, Colombie
- Recrutement
- Grupo Neurociencias de Antioquia
-
Contact:
- Yudy Milena León Varela
- E-mail: yudy.leon@gna.org.co
-
Chercheur principal:
- David Aguillon, MD
-
-
-
-
Songpa-Gu
-
Seoul, Songpa-Gu, Corée du Sud, 05505
- Recrutement
- Asan Medical Center
-
Contact:
- Jee Hoon Roh, MD, PhD
- Numéro de téléphone: 82-2-3010-3443
- E-mail: roh@amc.seoul.kr
-
Chercheur principal:
- Jae Hong Lee, MD, PhD
-
-
-
-
Catalonia
-
Barcelona, Catalonia, Espagne, 08036
- Suspendu
- Hospital Clinic Barcelona
-
-
-
-
-
Niigata, Japon
- Recrutement
- Niigata University
-
Chercheur principal:
- Takeshi Ikeuchi, MD
-
Contact:
- Sumie Tsuruki
- E-mail: sumietsuruki@bri.niigata-u.ac.jp
-
Contact:
- Maki Watanabe
- E-mail: m-watanabe@iris-aumn.co.jp
-
Osaka, Japon
- Suspendu
- Osaka City University
-
Tokyo, Japon
- Recrutement
- Tokyo University
-
Chercheur principal:
- Yoshiki Niimi, MD
-
Contact:
- Haruko Kuzuyamah
- E-mail: kuzuyamah@g.ecc.u-tokyo.ac.jp
-
-
-
-
Mexico City
-
Mexico City, Mexico City, Mexique, 14269
- Recrutement
- Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suarez"
-
Contact:
- Gabriela Rojas de la Torre, MS, MA
- E-mail: gabriella.delatorre.1066@gmail.com
-
Chercheur principal:
- Ana Luisa Sosa Ortiz, PHD
-
Sous-enquêteur:
- Erika Mariana Longoria Ibarrola, MD
-
-
-
-
-
Amsterdam, Pays-Bas, 1081HV
- Recrutement
- Amsterdam UMC
-
Contact:
- Bram Bongers
- E-mail: b.bongers@amsterdamumc.nl
-
Chercheur principal:
- Lisa Vermunt, MD,PhD
-
-
-
-
-
London, Royaume-Uni, WC1N 3BG
- Recrutement
- Institute of Neurology, Queen Square
-
Contact:
- Helen Rice, RN
- Numéro de téléphone: 07741 671 840
- E-mail: helen.rice2@nhs.net
-
Chercheur principal:
- Nick Fox, MD
-
-
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32224
- Recrutement
- Mayo Clinic Jacksonville
-
Chercheur principal:
- Gregory S Day, MD
-
Contact:
- Ercilia Moncayo
- E-mail: Moncayo.Ercilia@mayo.edu
-
Contact:
- Twila Morrell, BS
- E-mail: Morrell.Twila@mayo.edu
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Recrutement
- Indiana University-Indiana Alzheimer Disease Center
-
Contact:
- Jill Buck, RN
- Numéro de téléphone: 317-963-1847
- E-mail: jilmbuck@iu.edu
-
Chercheur principal:
- Martin Farlow, MD
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Recrutement
- Brigham and Women's Hospital
-
Chercheur principal:
- Jasmeer Chhatwal, MD, PhD
-
Contact:
- Alexa Coussoule
- E-mail: acoussoule@bwh.harvard.edu
-
Contact:
- Paola Matos
- E-mail: pmatos1@mgh.harvard.edu
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63108
- Recrutement
- Washington University in St. Louis School of Medicine
-
Chercheur principal:
- Randall Bateman, MD
-
Contact:
- McCrae Johnson, RN, MSN
- E-mail: mccrae@wustl.edu
-
Contact:
- Georgia Stobbs-Cucchi, RN
- E-mail: gstobbs@wustl.edu
-
-
New York
-
New York, New York, États-Unis, 10032
- Suspendu
- Columbia University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15260
- Recrutement
- University of Pittsburgh
-
Contact:
- Zana Ikonomovic, MD
- Numéro de téléphone: 412-692-2740
- E-mail: ikonomovics@upmc.edu
-
Chercheur principal:
- Sarah Berman, MD, PhD
-
-
Rhode Island
-
Providence, Rhode Island, États-Unis, 02906
- Recrutement
- Butler Hospital
-
Chercheur principal:
- Edward Huey, MD
-
Contact:
- Courtney Bodge, PhD
- Numéro de téléphone: (401) 455-6403
- E-mail: cbodge@butler.org
-
-
Washington
-
Seattle, Washington, États-Unis, 98195
- Recrutement
- University of Washington
-
Contact:
- Emmaline Seth
- E-mail: emmaseth@uw.edu
-
Chercheur principal:
- Suman Jayadev, MD
-
Contact:
- Sarah Taylor
- E-mail: saraht73@uw.edu
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Mutation carriers and non-carriers from families with a mutation (which is different from the genetic risk factor Apo-E4) known to cause Alzheimer's disease.
La description
Inclusion Criteria:
- Written informed consent obtained from participant and collateral source prior to any study-related procedures.
- Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.
- Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.
- Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.
- Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.
Exclusion Criteria:
- Under age 18
- Medical or psychiatric illness that would interfere in completing initial and follow-up visits
- Requires nursing home level care
- Has no one who can serve as a study informant
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Nombre de groupes / cohortes
Cohortes et interventions
Groupe / CohorteGroupe / Cohorte |
|---|
|
1
Mutation Positive |
|
2
Mutation Negative |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Pouvoir prédictif positif d'un biomarqueur ou d'un groupe de biomarqueurs
Délai: Évaluation de suivi variable basée sur l'âge par rapport à l'âge d'apparition du parent atteint.
|
Évaluation de suivi variable basée sur l'âge par rapport à l'âge d'apparition du parent atteint.
|
|
Biomarqueurs obtenus par prélèvement sanguin, ponction lombaire, IRM, FDG PET, PET imagerie amyloïde
Délai: Évaluation de suivi variable basée sur l'âge par rapport à l'âge d'apparition du parent atteint
|
Évaluation de suivi variable basée sur l'âge par rapport à l'âge d'apparition du parent atteint
|
|
Marqueurs cliniques également examinés à partir d'un entretien clinique et de tests cognitifs
Délai: Évaluation de suivi variable basée sur l'âge par rapport à l'âge d'apparition du parent atteint
|
Évaluation de suivi variable basée sur l'âge par rapport à l'âge d'apparition du parent atteint
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Les enquêteurs
Les enquêteurs
- Directeur d'études: Alisha Daniels, MD,MHA, (314) 273-9057
- Chercheur principal: Eric McDade, DO, Washington University School of Medicine
Publications et liens utiles
Publications générales
- Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006 Aug 8;67(3):446-52. doi: 10.1212/01.wnl.0000228230.26044.a4.
- Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007 Mar;64(3):343-9. doi: 10.1001/archneur.64.3.noc60123. Epub 2007 Jan 8.
- Godbolt AK, Cipolotti L, Anderson VM, Archer H, Janssen JC, Price S, Rossor MN, Fox NC. A decade of pre-diagnostic assessment in a case of familial Alzheimer's disease: tracking progression from asymptomatic to MCI and dementia. Neurocase. 2005 Feb;11(1):56-64. doi: 10.1080/13554790490896866.
- Morris JC, McKeel DW Jr, Storandt M, Rubin EH, Price JL, Grant EA, Ball MJ, Berg L. Very mild Alzheimer's disease: informant-based clinical, psychometric, and pathologic distinction from normal aging. Neurology. 1991 Apr;41(4):469-78. doi: 10.1212/wnl.41.4.469.
- Galvin JE, Powlishta KK, Wilkins K, McKeel DW Jr, Xiong C, Grant E, Storandt M, Morris JC. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study. Arch Neurol. 2005 May;62(5):758-65. doi: 10.1001/archneur.62.5.758.
- Prescott JW, Doraiswamy PM, Gamberger D, Benzinger T, Petrella JR; Dominantly Inherited Alzheimer Network. Diffusion Tensor MRI Structural Connectivity and PET Amyloid Burden in Preclinical Autosomal Dominant Alzheimer Disease: The DIAN Cohort. Radiology. 2022 Jan;302(1):143-150. doi: 10.1148/radiol.2021210383. Epub 2021 Oct 12.
- Gordon BA, Blazey TM, Su Y, Hari-Raj A, Dincer A, Flores S, Christensen J, McDade E, Wang G, Xiong C, Cairns NJ, Hassenstab J, Marcus DS, Fagan AM, Jack CR Jr, Hornbeck RC, Paumier KL, Ances BM, Berman SB, Brickman AM, Cash DM, Chhatwal JP, Correia S, Forster S, Fox NC, Graff-Radford NR, la Fougere C, Levin J, Masters CL, Rossor MN, Salloway S, Saykin AJ, Schofield PR, Thompson PM, Weiner MM, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol. 2018 Mar;17(3):241-250. doi: 10.1016/S1474-4422(18)30028-0. Epub 2018 Feb 1.
- Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11.
- Wagemann O, Li Y, Hassenstab J, Aschenbrenner AJ, McKay NS, Gordon BA, Benzinger TLS, Xiong C, Cruchaga C, Renton AE, Perrin RJ, Berman SB, Chhatwal JP, Farlow MR, Day GS, Ikeuchi T, Jucker M, Lopera F, Mori H, Noble JM, Sanchez-Valle R, Schofield PR, Morris JC, Daniels A, Levin J, Bateman RJ, McDade E, Llibre-Guerra JJ; Dominantly Inherited Alzheimer Network. Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network. Alzheimers Dement. 2024 Jan;20(1):47-62. doi: 10.1002/alz.13460. Epub 2023 Sep 23.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- IA0147
- U19AG102728 (Subvention/contrat des NIH des États-Unis)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .